HomeAI · summaries
Storia in 3 fonti
FDA approves Simtriyo for treating ADHD in children and adults
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
ilgazzettino.it
«Arriva un nuovo farmaco contro l'ADHD: come funziona e chi potrà utilizzarlo»
L'Otsuka Pharmaceutical Development & Commercializatio annunciato l'approvazione da parte della FDA della centanafadina orale (Simtriyo), un triplo inibitore della ricaptazione,...
- ·
medicalxpress.com
FDA approves Simtriyo for treating ADHD in children and adults
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and…
